Invivyd (IVVD) announced positive 12-month exploratory clinical efficacy data from the company’s ongoing CANOPY Phase 3 clinical trial of pemivibart, a half-life extended investigational monoclonal antibody, for the pre-exposure prophylaxis, PrEP, of COVID-19. The exploratory clinical efficacy data from follow-up months 7-12 in CANOPY Cohort B showed a relative risk reduction of 64% in the pemivibart arm compared to placebo in the likelihood of trial participants contracting confirmed symptomatic COVID-19. Continued protection over this follow-up period, absent continued dosing, was a prespecified exploratory endpoint and, added to initial 180-day clinical efficacy observations, generated an overall 12-month protection rate of 76% following two doses of pemivibart. The safety profile of pemivibart over the 12-month study period was reassuring with no new trends or safety signals observed for treatment-emergent adverse events or infusion-related reactions or hypersensitivity reactions since the disclosure of the 6-month CANOPY data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd announces FDA update on Pemgarda fact sheet for SARS-CoV-2 variants
- Invivyd provides virology data, analysis of SARS-CoV-2 structural biology
- Invivyd announces business readiness update, granted EUA for PEMGARDA
- Invivyd doses first participants in Phase 1 trial of VYD2311
- Invivyd’s Pemgarda shows neutralizing activity against SARS-CoV-2 variants